HOW MANAGEMENT SERVICES ORGANISATIONS ARE USED IN MEDICAL WEIGHT LOSSA structural explanation of the MSO and friendly-PC arrangement — what each entity holds, what the agreement between them typically covers, and which questions cannot be answered by anyone but your own healthcare attorney.

Educational overview · Approx. 10 min read · illustrative, not advice

A structural explanation of the MSO and friendly-PC arrangement — what each entity holds, what the agreement between them typically covers, and which questions cannot be answered by anyone but your own healthcare attorney.

Why This Three-Letter Acronym Keeps Appearing

If you have taken more than two calls about entering the metabolic or medical weight-loss category, someone has said "MSO" to you, usually in a tone implying the matter is settled. It is not settled, and the confidence is the part to be suspicious of. The structure is real, widely used and well documented — but it is a framework with a large amount of state-specific detail inside it, and the detail is where the risk lives.

This page is a structural explanation. It describes what the entities are, what they typically hold, and what the agreement between them usually covers. It does not tell you that any structure is permitted in your state, because that is not a thing an article can tell you. Atlas Metabolic is not a law firm and nothing here is legal advice.

If you have not yet separated the two questions underneath this one — owning a business versus practicing medicine — start with whether you need to be a doctor to own a GLP-1 clinic and come back. The MSO discussion only makes sense once that distinction is clean in your head.

What a Management Services Organisation Actually Is

A management services organisation is an ordinary business entity that provides non-clinical services to a medical practice under contract. It is not a special legal creature and it does not hold a licence of its own. It is a vendor with an unusually broad and unusually integrated scope of work.

Its reason for existing is the corporate practice of medicine doctrine, described in an April 2025 Milbank Memorial Fund issue brief as a body of state-level rules barring unlicensed persons and corporations from owning or controlling medical practices or employing physicians for clinical care, intended to preserve independent medical judgment. Milbank identifies MSOs as the mechanism used to separate business functions from clinical care.

The consequential sentence in that brief is not the definition. It is this: enforcement risk turns on the degree of control the MSO exercises over clinical operations and professional judgment. An MSO is not a permission slip. It is a description of where the boundary is drawn, and drawing it on paper is not the same as respecting it in operation.

The Friendly-PC Arrangement, Described Plainly

The paired structure usually gets called a friendly-PC arrangement. A professional entity — a professional corporation or professional LLC depending on the state — is owned by a licensed clinician and holds everything clinical: the clinicians, the clinical decisions, the medical records, the professional liability. The MSO, owned by the business side, holds everything else and contracts with the professional entity to supply it.

The word "friendly" refers to the relationship between the parties rather than to any legal category, and it is where the arrangement gets fragile. The business side typically wants continuity — assurance that the professional entity's ownership does not become chaotic if the owner-clinician leaves, dies or is disciplined. The mechanisms used to provide that continuity are also the mechanisms most likely to be read as control. That tension is the whole ballgame, and it is a question for counsel every single time.

Note what does not change under any version of this: the professional entity must be able to say no. A member declined, a renewal declined, a dose declined — without commercial override. A model whose numbers only work if nobody is ever turned away has already answered the compliance question badly.

What a Management Services Agreement Typically Covers

The management services agreement is the document that does the work, and reading a real one is a better education than reading ten explainers. Scope commonly includes, in broad terms:

• Administrative and back-office services: bookkeeping, accounts payable, vendor management, reporting
• Non-clinical personnel: recruiting, employing and supervising administrative, marketing and support staff
• Technology: practice management and telehealth platforms, member-facing applications, data infrastructure and security administration
• Marketing and member acquisition, including brand, creative, media buying and intake operations
• Facilities, equipment and supplies on the non-clinical side, including leases and furnishings
• Purchasing and supply-chain coordination for non-clinical goods and services
• Compliance support functions, distinct from clinical policy-setting
• Term, termination, indemnification, restrictive covenants, insurance requirements and dispute resolution

The Line the Agreement Cannot Be Written Across

The corresponding list is shorter and far more important. Clinical judgment, the standard of care, whether an individual member should be prescribed anything at all, agent and dose selection, clinical protocols and monitoring, credentialing and clinical supervision of clinicians, and ultimate control of the medical record are the professional entity's, and the doctrine exists specifically to keep them there.

This is where careless operators create exposure without noticing. Marketing that promises a specific clinical outcome before any clinician has evaluated anyone is a business-side act with clinical consequences. So is a compensation design that rewards the volume of prescriptions written. So is an intake flow that treats clinician review as a formality to be cleared rather than a decision that can genuinely go either way.

Product durability sits alongside this. FDA declared the injectable semaglutide shortage resolved on 21 February 2025, with 503A enforcement discretion ending 22 April 2025 and 503B on 22 May 2025, and removed tirzepatide from the shortage list in December 2024. On 30 April 2026 FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need and expressly rejecting affordability and insurance access as constituting clinical need; the comment period was extended to 30 July 2026. IQVIA reported in October 2025 that compounded prescribing did not abate after delisting and that over 80% of compounded prescriptions include supplemental ingredients. Any structure whose supply assumption depends on how that proceeding resolves is carrying a risk no entity chart mitigates — see how supplement and pharmaceutical supply chains actually work for the mechanics.

The Money Question Is the Hard One

Everything above is comparatively settled. How the MSO is paid is not, and it is the question most often waved through on a sales call and then re-litigated expensively later.

The categories you will hear discussed are a flat fee, a cost-plus fee, a fair-market-value fee for defined services, or a percentage of practice collections. Each raises a different set of questions under state fee-splitting rules and under federal and state fraud-and-abuse rules, and we are not going to tell you which of them is acceptable anywhere, because that determination is jurisdiction-specific and fact-specific and belongs to your counsel.

What we will do is tell you which questions to make them answer. Does this state restrict sharing of professional fees with a non-licensed entity, and does the proposed fee structure implicate that restriction? Is the fee supportable as fair market value for services actually delivered, and what documentation supports it? Does anything anywhere in the model touch federal healthcare programme dollars — and do not assume a cash-pay model automatically sits outside every rule, ask the question properly. Are there referral relationships, marketing arrangements or vendor rebates that need separate analysis? Our compliance basics for wellness businesses covers the general posture; the specifics are counsel's.

Control Is the Variable Under Examination

If you read only one thing about MSO risk, read this: the analysis is functional, not formal. Milbank frames enforcement risk around the degree of control exercised over clinical operations and professional judgment. That means an examiner is looking at how the business actually runs, not at the diagram on page four of the deck.

So the honest diligence question is not "do we have an MSO structure" but "if someone reconstructed how decisions actually get made here from emails, dashboards and compensation, what picture would they form?" That is a harder question and a better one. We built a version of it into the due diligence checklist for evaluating any opportunity in this category.

State direction of travel reinforces the point. Massachusetts enacted MSO ownership transparency requirements in 2025, and CPOM-strengthening bills were introduced in Oregon, Washington and California. A structure designed to be just barely defensible under 2024 rules is not a durable asset.

Multi-State Adds Layers, Not Copies

Buyers frequently assume expanding beyond one market is a matter of repeating the structure. It is not, for two reasons. First, CPOM rules vary by state in substance, so the professional entity's form, ownership and permitted arrangements can differ across the map. Second, medical practice is generally deemed to occur where the patient is located, so clinicians typically must be licensed in the patient's state; the Interstate Medical Licensure Compact covered up to 43 member states as of March 2026, which streamlines a pathway without eliminating the requirement.

The practical consequence is that a multi-state plan is a licensure plan and a legal-structure plan before it is a marketing plan. That is why we treat expansion as a sequenced decision rather than an assumption, and why the sequencing is documented on the expansion path rather than promised on a call.

Note also the language question. Nothing in an MSO arrangement creates or protects geography. Franchise systems sell territory; a licence to a business build does not, and no page on this site will tell you otherwise. If you have not read the difference between a franchise and a licence, that comparison is worth an hour before any structural conversation.

What Your Counsel Has to Answer Before You Sign Anything

Bring this to a healthcare attorney licensed where your members will be located — not to your corporate lawyer, and not to a consultant.

• Does this state permit the contemplated arrangement between a professional entity and a management entity, and what recent enforcement or legislation bears on that?
• Which specific provisions in the draft management services agreement would an examiner read as control over clinical operations?
• How may the management fee be calculated here, and what fee-splitting or fraud-and-abuse analysis applies?
• What continuity mechanisms for the professional entity's ownership are defensible in this state, and which are not?
• Who owns the medical record, and who owns the non-clinical member data — and are those answers consistent with the agreement as drafted?
• What happens on termination: how do members, records, technology and brand unwind?
• Which of these answers change if we open in a second state, and which have to be redone from scratch?

Where Atlas Sits, and What Happens Next

Atlas Metabolic provides no medical services and employs no clinicians, ever. Atlas licenses a business build — telehealth stack, ordering system, member coaching technology, brand kit and operational playbooks — to a partner, and clinical care is delivered by a separately licensed medical entity that is clinically independent. Atlas does not direct clinical decisions and does not sit inside the clinical entity. How that separation is expressed in the build is set out in how the build works and in our compliance position.

Ask Atlas to put this in writing: whether Atlas or the partner engages counsel to structure the partner's professional entity and management services agreement, and what Atlas explicitly does not do in that process

Commercially, Atlas charges a one-time license fee, takes 0% of revenue and charges no ongoing partner fees — a deliberate structural choice rather than a discount, and one that removes an entire category of ongoing entanglement between the licensor and the operating business. The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own. If you want that contrast in arithmetic rather than adjectives, read what a royalty really costs over a full term.

Atlas takes a limited number of partner builds — Ask Atlas to put this in writing: partner slots per quarter — and the fit call decides in both directions. It is a qualification conversation, not a sales call, and it is entirely reasonable for it to end with either side declining. If you have counsel lined up and the questions above written down, submit the partner application and bring them to the call. Structural questions are the ones we would rather answer early, on the record, than have you discover after signing something.

FREQUENTLY ASKED QUESTIONS.